neurexin I Inhibitors
Neurexin I inhibitors comprise a diverse group of chemicals that exert their influence either directly or indirectly on the function of neurexin I, a key player in synaptic processes. Tetrodotoxin, a voltage-gated sodium channel blocker, disrupts neuronal signaling by inhibiting sodium influx, indirectly impeding neurexin I-mediated synaptic processes that rely on proper action potentials for function. Anisomycin, a protein synthesis inhibitor, indirectly modulates neurexin I through its effects on the MAPK/ERK pathway, altering neurexin I activity by disrupting the translation process. Other indirect inhibitors, such as Wortmannin, Nimodipine, KN-62, Rapamycin, LY294002, A23187, Staurosporine, U0126, SP600125, and 2-Aminoethyl diphenylborinate, target various signaling pathways, including PI3K/AKT, mTOR, CaMKII, JNK, and TRPC channels, influencing neurexin I function at the synapse.
These chemicals demonstrate the intricate network of signaling pathways that converge on neurexin I, showcasing the complexity of its regulation. The indirect inhibitors exert their effects by disrupting these pathways, leading to altered neurexin I activity and ultimately impacting synaptic processes. Understanding the nuanced interactions between these chemicals and neurexin I provides valuable insights into the molecular mechanisms governing synaptic function, offering avenues for targeted modulation in the context of neuroscientific research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin, a protein synthesis inhibitor, impacts neurexin I indirectly through its effects on the MAPK/ERK pathway. Anisomycin inhibits protein synthesis by blocking the peptidyl transferase reaction during translation. As neurexin I function is influenced by ERK signaling, disruption of this pathway by Anisomycin results in altered neurexin I activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly modulates neurexin I by disrupting the PI3K/AKT pathway. Neurexin I function is linked to PI3K/AKT signaling, and Wortmannin's inhibition of PI3K attenuates this pathway, leading to downstream effects on neurexin I activity at the synapse. | ||||||
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $61.00 $307.00 | 2 | |
Nimodipine, a voltage-gated calcium channel blocker, indirectly influences neurexin I by modulating calcium-dependent processes. Neurexin I, involved in calcium-dependent exocytosis, relies on proper calcium influx for synaptic function. Nimodipine's inhibition of calcium channels disrupts this influx, indirectly impacting neurexin I-mediated neurotransmitter release and synaptic communication. | ||||||
KN-62 | 127191-97-3 | sc-3560 | 1 mg | $136.00 | 20 | |
KN-62, a Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor, indirectly affects neurexin I through the modulation of CaMKII signaling. Neurexin I interacts with CaMKII, and KN-62 inhibits CaMKII, disrupting its downstream effects on neurexin I function. This indirect modulation alters the phosphorylation status of neurexin I, influencing its involvement in synaptic processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, indirectly influences neurexin I by disrupting mTOR signaling. Neurexin I is linked to mTOR-regulated pathways, and Rapamycin's inhibition of mTOR alters the downstream signaling cascades that impact neurexin I function at the synapse. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly modulates neurexin I by disrupting the PI3K/AKT pathway. Neurexin I function is intertwined with PI3K/AKT signaling, and LY294002's inhibition of PI3K attenuates this pathway, leading to downstream effects on neurexin I activity in synaptic processes. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187, a calcium ionophore, indirectly impacts neurexin I by promoting calcium influx. Neurexin I function involves calcium-dependent processes at the synapse, and A23187 facilitates calcium entry into cells. This indirect modulation enhances neurexin I-mediated synaptic activities by promoting the availability of calcium ions required for proper neurotransmitter release and synaptic communication. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a broad-spectrum protein kinase inhibitor, indirectly influences neurexin I by affecting multiple signaling pathways. Neurexin I is connected to various kinases, and Staurosporine's inhibition of these kinases disrupts downstream signaling cascades, altering neurexin I function. This broad-spectrum inhibition results in a comprehensive impact on neurexin I-mediated synaptic processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, indirectly modulates neurexin I by disrupting JNK signaling. Neurexin I is connected to JNK, and SP600125's inhibition of JNK alters downstream signaling cascades, influencing neurexin I function. This indirect modulation results in altered phosphorylation patterns of neurexin I, impacting its role in synaptic processes. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
2-APB, a TRPC channel blocker, indirectly influences neurexin I by modulating calcium influx. Neurexin I function involves TRPC channels, and 2-Aminoethyl diphenylborinate's inhibition of TRPC channels disrupts calcium entry, indirectly impacting neurexin I-mediated synaptic processes by altering the availability of calcium ions required for proper neurotransmitter release. | ||||||